Managing Myositis

<p>Foreword.- 1 Introduction to Myositis.- 2 Myositis Basics/Who Gets Myositis.- 3 Evaluating the patient with suspected myositis.- 4 Asymptomatic HyperCKemia.- 5 Clinical Features of Myositis Patients: Muscular Manifestations.- 6 Clinical Features of Myositis Patients: Skin Manifestations.- 7 Clinical Features of Myositis Patients: Lung Manifestations.- 8 Clinical Features of Myositis Patients: Cardiac Manifestations.- 9 Clinical Features of Myositis Patients: Juvenile Dermatomyositis clinical features.- 10 Clinical Features of Myositis Patients: Other manifestations: arthritis, Raynaud phenomenon, constitutional.- 11 Making the Diagnosis of Myositis: Beyond the History and Physical Examination: Definition and classification of Myositis.- 12 Making the Diagnosis of Myositis: Beyond the History and Physical Examination: Electrodiagnostic Testing.- 13 Making the Diagnosis of Myositis: Beyond the History and Physical Examination: Muscle biopsy and interpretation.- 14 Making the Diagnosisof Myositis: Beyond the History and Physical Examination: Skin biopsy and interpretation.- 15 Making the Diagnosis of Myositis: Beyond the History and Physical Examination: Lung biopsy and interpretation.- 16 Making the Diagnosis of Myositis: Beyond the History and Physical Examination: Muscle MRI.- 17 Making the Diagnosis of Myositis: Beyond the History and Physical Examination: Laboratory testing in myositis.- 18 Role of ANA and Myositis Autoantibodies in Diagnosis.- 19 Role of Myositis Autoantibodies in Management and Prognosis.- 20 Traditional Myositis Autoantibodies:&nbsp; Synthetase, Mi-2, SRP, Ku, PM-Scl, Ro, U1RNP.- 21 Dermatomyositis-associated Autoantibodies: TIF1-γ, NXP2, and MDA5.- 22 Newly described Myositis Autoantibodies: HMGCR, NT5C1A, SAE, PUF60.- 23 Myositis Mimics: The Differential Diagnosis of Myositis.- 24 Immune Mediated Necrotizing Myopathy (IMNM).- 25 Cancer Associated Myositis.- 26 Myositis Associated Interstitial Lung Disease.- 27 Pregnancy in Myositis.- 28 Pathogenesis of Myositis.- 29 Management Considerations: Pharmacologic intervention.- 30 Management Considerations:Special treatment considerations - JDM.- 31 Management Considerations: Special treatment considerations - Refractory skin rash and calcinosis.- 32 Management Considerations: Special treatment considerations - ILD.- 33 Role of Exercise in the Management of Myositis.- 34 Dietary Considerations in Myositis.- 35 Distinguishing Disease Activity and Damage in Myositis.</p>